Histamine H1 Receptor BPND of 11C-Doxepine for the Various Regions Measured with PET at Baseline and After Administration of 5 mg of Olopatadine in Acute and Chronic Scans
BPND | ||||
---|---|---|---|---|
Region | Baseline | Acute (0 wk) | Chronic (4 wk) | Acute scan receptor occupancy |
DLPFC | 0.28 ± 0.06 | 0.24 ± 0.07 | 0.13 ± 0.08* | 15% ± 15% |
Frontobasal | 0.33 ± 0.08 | 0.27 ± 0.07† | 0.15 ± 0.08* | 18% ± 15% |
Parietal | 0.25 ± 0.05 | 0.20 ± 0.08 | 0.09 ± 0.08* | 24% ± 24% |
Temporal | 0.37 ± 0.07 | 0.33 ± 0.08 | 0.21 ± 0.09* | 11% ± 12% |
Occipital | 0.19 ± 0.04 | 0.16 ± 0.06 | 0.09 ± 0.05* | 19% ± 22% |
Anterior cingulate | 0.29 ± 0.07 | 0.26 ± 0.07 | 0.13 ± 0.09* | 14% ± 14% |
Thalamus | 0.26 ± 0.07 | 0.18 ± 0.06† | 0.20 ± 0.06 | 26% ± 20% |